Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Core Viewpoint - Aligos Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 6, 2025, before the U.S. financial markets open, indicating ongoing developments in its clinical-stage biotechnology efforts focused on liver and viral diseases [1]. Company Overview - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to improving patient outcomes through the development of best-in-class therapies for liver and viral diseases [2]. - The company utilizes a science-driven approach and extensive R&D expertise to advance its pipeline of therapeutics targeting high unmet medical needs, including chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses [2].